Larimar Therapeutics (LRMR) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 31.6% versus a loss of 44.0%. Over five years, LRMR leads with a -77.7% price change compared with -83.1% for PYXS. Larimar Therapeutics is the larger company by market cap ($280.5 million vs $237.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | PYXS |
|---|---|---|
| Share price | $2.70 | $1.99 |
| Market cap | $280.48M | $237.72M |
| 1-day change | -1.82% | -1.00% |
| YTD return | -29.13% | +73.04% |
| 1-year return | -43.98% | -31.62% |
| 5-year return | -77.72% | -83.09% |
| EPS (TTM) | $-1.99 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $5.55 |
| 52-week low | $2.61 | $1.03 |
| Distance from 52-week high | -57.94% | -64.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +433.33% | +335.68% |
| Average volume | 1.27M | 1.26M |
| Shares outstanding | 103.88M | 119.46M |
| Employees | 71 | 56 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYXS has outperformed LRMR by 12.4 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Healthcare · Biotechnology · 71 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Healthcare · Biotechnology · 56 employees
LRMR vs PYXS FAQ
Which is bigger, Larimar Therapeutics or Pyxis Oncology?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $280.48M compared with $237.72M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, LRMR or PYXS?
PYXS returned -31.62% over the past 12 months, compared with -43.98% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.